A new drug called Imdelltra has been approved by the FDA for the treatment of small cell lung cancer. This aggressive type of cancer often relapses after chemotherapy, but Imdelltra offers a new treatment option. The drug is an immunotherapy that targets a protein abundant in small cell lung cancer cells. Clinical trial results showed promising response rates and overall survival rates in patients who had not responded to previous treatments. Imdelltra carries a black box warning for potential side effects, but the high unmet need for effective treatments in small cell lung cancer suggests that the drug has blockbuster potential.
Source link
Amgen Drug for Aggressive Type of Lung Cancer Wins Accelerated FDA Approval
